{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:03Z","timestamp":1787020743290,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Travere Therapeutics, Inc.","award":["Travere Therapeutics, Inc."],"award-info":[{"award-number":["Travere Therapeutics, Inc."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Zellweger spectrum disorders (ZSDs) are a rare, heterogenous group of autosomal recessively inherited disorders characterized by reduced peroxisomes numbers, impaired peroxisomal formation, and\/or defective peroxisomal functioning. In the absence of functional peroxisomes, bile acid synthesis is disrupted, and multisystem disease ensues with abnormalities in the brain, liver, kidneys, muscle, eyes, ears, and nervous system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>Liver disease may play an important role in morbidity and mortality, with hepatic fibrosis that can develop as early as the postnatal period and often progressing to cirrhosis within the first year of life. Because hepatic dysfunction can have numerous secondary effects on other organ systems, thereby impacting the overall disease severity, the treatment of liver disease in patients with ZSD is an important focus of disease management. Cholbam\u00ae (cholic acid), approved by the U.S. Food and Drug Administration in March 2015, is currently the only therapy approved as adjunctive treatment for patients with ZSDs and single enzyme bile acid synthesis disorders. This review will focus on the use of CA therapy in the treatment of liver disease associated with ZSDs, including recommendations for initiating and maintaining CA therapy and the limitations of available clinical data supporting its use in this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cholbam is a safe and well-tolerated treatment for patients with ZSDs that has been shown to improve liver chemistries and reduce toxic bile acid intermediates in the majority of patients with ZSD. Due to the systemic impacts of hepatic damage, Cholbam should be initiated in patients without signs of advanced liver disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-021-01940-z","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T06:02:59Z","timestamp":1631599379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cholbam\u00ae and Zellweger spectrum disorders: treatment implementation and management"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6476-9578","authenticated-orcid":false,"given":"Janaina Nogueira","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zineb","family":"Ammous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemen","family":"Eroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Heubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Himes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirish","family":"Palle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"issue":"2","key":"1940_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209\u201318.","journal-title":"J Clin Invest"},{"issue":"4","key":"1940_CR2","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1074\/jbc.275.4.2247","volume":"275","author":"SL Friedman","year":"2000","unstructured":"Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275(4):2247\u201350.","journal-title":"J Biol Chem"},{"key":"1940_CR3","unstructured":"National Organization for Rare Disorders. Zellweger spectrum disorders. 2016. https:\/\/rarediseases.org\/rare-diseases\/zellweger-spectrum-disorders\/. Accessed 15 Mar 2021."},{"key":"1940_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13023-015-0368-9","volume":"10","author":"FC Klouwer","year":"2015","unstructured":"Klouwer FC, Berendse K, Ferdinandusse S, Wanders RJ, Engelen M, Poll-The BT. Zellweger spectrum disorders: clinical overview and management approach. Orphanet J Rare Dis. 2015;10:151.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"1940_CR5","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2174\/138920012803762747","volume":"13","author":"RJ Wanders","year":"2012","unstructured":"Wanders RJ, Ferdinandusse S. Peroxisomes, peroxisomal diseases, and the hepatotoxicity induced by peroxisomal metabolites. Curr Drug Metab. 2012;13(10):1401\u201311.","journal-title":"Curr Drug Metab"},{"issue":"10","key":"1940_CR6","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1016\/j.bbadis.2019.06.013","volume":"1865","author":"K Berendse","year":"2019","unstructured":"Berendse K, Boek M, Gijbels M, et al. Liver disease predominates in a mouse model for mild human Zellweger spectrum disorder. Biochim Biophys Acta Mol Basis Dis. 2019;1865(10):2774\u201387.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"3","key":"1940_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ymgme.2015.12.009","volume":"117","author":"NE Braverman","year":"2016","unstructured":"Braverman NE, Raymond GV, Rizzo WB, et al. Peroxisome biogenesis disorders in the Zellweger spectrum: an overview of current diagnosis, clinical manifestations, and treatment guidelines. Mol Genet Metab. 2016;117(3):313\u201321.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"1940_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ddrr.1113","volume":"17","author":"NE Braverman","year":"2013","unstructured":"Braverman NE, D\u2019Agostino MD, Maclean GE. Peroxisome biogenesis disorders: biological, clinical and pathophysiological perspectives. Dev Disabil Res Rev. 2013;17(3):187\u201396.","journal-title":"Dev Disabil Res Rev"},{"issue":"3","key":"1940_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1159\/000494555","volume":"12","author":"JE Heubi","year":"2018","unstructured":"Heubi JE, Bishop WP. Long-term cholic acid treatment in a patient with Zellweger spectrum disorder. Case Rep Gastroenterol. 2018;12(3):661\u201370.","journal-title":"Case Rep Gastroenterol"},{"issue":"5","key":"1940_CR10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.bbamcr.2015.11.015","volume":"1863","author":"HR Waterham","year":"2016","unstructured":"Waterham HR, Ferdinandusse S, Wanders RJ. Human disorders of peroxisome metabolism and biogenesis. Biochim Biophys Acta. 2016;1863(5):922\u201333.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"1940_CR11","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/hep.21532","volume":"45","author":"MH Keane","year":"2007","unstructured":"Keane MH, Overmars H, Wikander TM, et al. Bile acid treatment alters hepatic disease and bile acid transport in peroxisome-deficient PEX2 Zellweger mice. Hepatology. 2007;45(4):982\u201397.","journal-title":"Hepatology"},{"issue":"3","key":"1940_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ymgme.2008.11.165","volume":"96","author":"S Ferdinandusse","year":"2009","unstructured":"Ferdinandusse S, Denis S, Dacremont G, Wanders RJ. Toxicity of peroxisomal C27-bile acid intermediates. Mol Genet Metab. 2009;96(3):121\u20138.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"1940_CR13","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1053\/j.gastro.2009.07.043","volume":"137","author":"E Gonzales","year":"2009","unstructured":"Gonzales E, Gerhardt MF, Fabre M, et al. Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy. Gastroenterology. 2009;137(4):1310-20.e1\u20133.","journal-title":"Gastroenterology."},{"key":"1940_CR14","unstructured":"US Food and Drug Administration. FDA approves Cholbam to treat rare bile acid synthesis disorders [press release]. 2015. https:\/\/wayback.archive-it.org\/7993\/20170112023805\/http:\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm438572.htm. Accessed 15 Mar 2021."},{"issue":"4","key":"1940_CR15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/hep.27964","volume":"62","author":"JYL Chiang","year":"2015","unstructured":"Chiang JYL. Negative feedback regulation of bile acid metabolism: impact on liver metabolism and diseases. Hepatology. 2015;62(4):1315\u20137.","journal-title":"Hepatology"},{"issue":"3","key":"1940_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","volume":"6","author":"B Goodwin","year":"2000","unstructured":"Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6(3):517\u201326.","journal-title":"Mol Cell"},{"issue":"6","key":"1940_CR17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s10545-016-9962-9","volume":"39","author":"K Berendse","year":"2016","unstructured":"Berendse K, Klouwer FC, Koot BG, et al. Cholic acid therapy in Zellweger spectrum disorders. J Inherit Metab Dis. 2016;39(6):859\u201368.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"1940_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.1840150206","volume":"15","author":"KD Setchell","year":"1992","unstructured":"Setchell KD, Bragetti P, Zimmer-Nechemias L, et al. Oral bile acid treatment and the patient with Zellweger syndrome. Hepatology. 1992;15(2):198\u2013207.","journal-title":"Hepatology"},{"issue":"3","key":"1940_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/MPG.0000000000001657","volume":"65","author":"JE Heubi","year":"2017","unstructured":"Heubi JE, Bove KE, Setchell KDR. Oral cholic acid is efficacious and well tolerated in patients with bile acid synthesis and Zellweger spectrum disorders. J Pediatr Gastroenterol Nutr. 2017;65(3):321\u20136.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"1940_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/jimd.12042","volume":"42","author":"FCC Klouwer","year":"2019","unstructured":"Klouwer FCC, Koot BGP, Berendse K, et al. The cholic acid extension study in Zellweger spectrum disorders: results and implications for therapy. J Inherit Metab Dis. 2019;42(2):303\u201312.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"1940_CR21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/MPG.0000000000002618","volume":"70","author":"JE Heubi","year":"2020","unstructured":"Heubi JE, Setchell KDR. Open-label phase 3 continuation study of cholic acid in patients with inborn errors of bile acid synthesis. J Pediatr Gastroenterol Nutr. 2020;70(4):423\u20139.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"1940_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000490095","volume":"12","author":"JE Heubi","year":"2018","unstructured":"Heubi JE, Setchell KDR, Bove KE. Long-term cholic acid therapy in Zellweger Spectrum Disorders. Case Rep Gastroenterol. 2018;12(2):360\u201372.","journal-title":"Case Rep Gastroenterol"},{"key":"1940_CR23","unstructured":"CHOLBAM\u00ae (cholic acid) capsules, for oral use [prescribing information]. San Diego, CA: Manchester Pharmaceuticals, Inc.; 2020."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01940-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01940-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01940-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T06:09:12Z","timestamp":1631599752000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01940-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1940"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01940-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"17 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JN: Consulting for Travere Therapeutics. ZA: Consulting and speaking for Travere Therapeutics (2018\u20132019); advisory board for BioMarin (2018) and Travere Therapeutics (2017). YE: Consulting for Travere Therapeutics. EH: Consulting for Travere Therapeutics. JH: Equity interest in Asklepion; consulting for Alnylam, FrieslandCampina, Travere Therapeutics, Mirum, and Albireo. RH: Consulting and speaking for Alexion and Travere Therapeutics. SP: Consulting for Travere Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"388"}}